Objective-IGF-1 (insulin-like growth factor 1) is a major autocrine/paracrine growth factor, which promotes cell proliferation, migration, and survival. We have shown previously that IGF-1 reduced atherosclerosis and promoted features of stable atherosclerotic plaque in Apoe −/− mice-an animal model of atherosclerosis. The aim of this study was to assess effects of smooth muscle cell (SMC) IGF-1 signaling on the atherosclerotic plaque. Approach and Results-We generated Apoe −/− mice with IGF1R (IGF-1 receptor) deficiency in SMC and fibroblasts (SM22α [smooth muscle protein 22 α]-CreKI/IGF1R-flox mice). IGF1R was decreased in the aorta and adventitia of SM22α-CreKI/ IGF1R-flox mice and also in aortic SMC, embryonic, skin, and lung fibroblasts isolated from SM22α-CreKI/IGF1R-flox mice. IGF1R deficiency downregulated collagen mRNA-binding protein LARP6 (La ribonucleoprotein domain family, member 6) and vascular collagen, and mice exhibited growth retardation. The high-fat diet-fed SM22α-CreKI/IGF1R-flox mice had increased atherosclerotic burden and inflammatory responses. α-SMA (α-smooth muscle actin)-positive plaque cells had reduced proliferation and elevated apoptosis. SMC/fibroblast-targeted decline in IGF-1 signaling decreased atherosclerotic plaque SMC, markedly depleted collagen, reduced plaque fibrous cap, and increased plaque necrotic cores. Aortic SMC isolated from SM22α-CreKI/IGF1R-flox mice had decreased cell proliferation, migration, increased sensitivity to apoptosis, and these effects were associated with disruption of IGF-1-induced Akt signaling. 
I
GF-1 (insulin-like growth factor 1) mediates somatic development and growth, and IGF-1 deficiency delays puberty and induces multiple growth abnormalities. 1 Circulating IGF-1 levels are maximal during early childhood; however, they progressively decline with age, 2 and reduced IGF-I in the elderly may contribute to the increased risk of cardiovascular diseases. 3 Cardiovascular diseases, including atherosclerotic heart disease, remain the primary cause of morbidity and mortality in the United States. 4 Most acute coronary events are related to rupture or erosion of atherosclerotic plaques that are not hemodynamically significant. 5 Thus, plaque stability is a critical determinant of clinical events. We have shown that systemic IGF-1 administration in Apoe −/− mice-an animal model of atherosclerosis-reduced atherosclerosis, decreased inflammatory responses, and promoted features of stable atherosclerotic plaque. 6, 7 Consistent with our results, another group reported that administration of long R3 IGF-1 increased plaque smooth muscle cells (SMCs), cap thickness, and reduced the rate of intraplaque hemorrhage, indicating that IGF-1 promoted plaque stabilization. 8 These findings are in line with most (but not all 9 ) clinical studies, which have suggested that lower circulating IGF-1 levels and higher IGFBP (IGF-1-binding protein)-3 are associated with an increased risk of atherosclerotic disease. 10, 11 Most actions of IGF-1 are mediated via its cognate receptor tyrosine kinase, IGF1R (IGF-1 receptor).
12 IGF1R signaling activates multiple downstream signaling pathways, including PI3-kinase, Akt, and MAPK (mitogen-activated protein kinase). The activation of these pathways mediates differential biologic actions of IGF-1, including cell growth, differentiation, migration, and survival. 12 Reduced levels of IGF-1 and IGF1R were associated with apoptotic SMC in advanced human atherosclerotic plaque 13 suggesting a link between downregulation of IGF-1 signaling, SMC apoptosis, and atherosclerotic burden. IGF1R is ubiquitously expressed; therefore, multiple cell types can mediate IGF-1-induced effects on atherosclerotic plaque development. An animal model with cell-specific IGF1R deficiency is thus an indispensable tool to delineate the contribution of intracellular IGF-1 signaling to net IGF-1 effects. We have demonstrated recently that IGF1R deficiency in macrophages decreased expression of cholesterol transporters, reduced lipid efflux, and increased foam cell accumulation in lesions, which in turn resulted in elevated atherosclerotic burden and reduced plaque vulnerability. 14 SMC and adventitial fibroblasts are major vascular cell types determining normal vessel wall function and development, repair, and response to atherogenesis. 15 IGF-1 promotes vascular SMC migration, proliferation, and survival; however, the specific contribution of SMC in IGF-1-induced atheroprotective effects is unknown. In the current study, we aimed to assess the role of SMC IGF-1 signaling on the atherosclerotic plaque. For this purpose, we crossbred Igf1r-floxed mice with SM22α (smooth muscle protein 22α)-Cre knockin (SM22α-CreKI) mice, both nullizygous for the Apoe gene (Apoe −/− ), anticipating to induce IGF1R deficiency in SM22α-expressing cell types, that is, SMCs. Cre recombinase expression and reduced IGF1R level were detected in SM22α-CreKI/IGF1R-flox mice in SMC-rich organs and also, unexpectedly, in fibroblast-rich vascular adventitia. We assessed the effect of SMC and fibroblast-targeted IGF1R deficiency on vascular wall morphology, atherosclerotic plaque composition, atherosclerotic burden, and plaque stability. We found that IGF1R deficiency reduced vessel size, depleted vascular collagen, and increased atherosclerosis. Our results establish the critical importance of IGF-1 signaling for normal vascular wall development and for atheroprotection.
Materials and Methods
The authors declare that all supporting data are available within the article (and its online supplementary files).
Mice
All animal experiments were approved by the Institutional Committee for Use and Care of Laboratory Animals of University of Missouri at Columbia. Mice with SM22α Cre recombinase knockin (SM22α-CreKI +/+ mice) were obtained from Dr Eugene Chen (Medical School, University of Michigan). 16 Mice with LoxP-flanked IGF1R were a generous gift from Dr Jens Bruning (University of Leipzig, Germany). 17 
Cells
Aortic SMCs were isolated by attaching the adventitial fat-cleaned, opened aorta to the culture dishes containing DMEM/F-12 media (Thermo Fisher), supplemented with 10% fetal bovine serum, 4 mmol/L L-glutamine, 100 U/mL penicillin, and 100 ug/mL streptomycin. Cell identity was confirmed by staining for calponin and α-SMA (α-smooth muscle actin), SMC markers. More than 90% cells were double positive for calponin and α-SMA ( Figure I in the online-only Data Supplement). Mouse embryonic fibroblasts were harvested according to the standard protocol. 18 Mouse adult skin and lung fibroblasts were isolated as per Seluanov et al. 19 Briefly, mouse lung and skin tissue was minced and treated with 0.14 U/mL Liberase Blendzyme collagenase mixture (Roche) in EMEM (Eagle's minimal essential medium)/F-12 media for 60 minutes, and tissue fragments were left to attach to the culture dish for 48 hours. Fibroblast identity was confirmed by immunostaining for ER-TR7-a fibroblast marker. 20 We used male mice for cell isolation.
Atherosclerosis Quantification
Under anesthesia, mice were perfused with saline and then 4% buffered paraformaldehyde plus 5% sucrose, and the heart and the entire aorta were dissected. The heart was separated from the aortic arch and fixed overnight followed by embedding into paraffin. Three aortic valve equally spaced sections were stained with H&E (haemotoxylin and eosin) and lesions were manually outlined with CellSense Dimension software (Olympus) by 2 investigators blinded to the group assignment. For the current study, the average internal variability (sectionto-section coefficient of variation per mouse) was 9.5±0.7%, external variability (mice-to-mice variability within group) was 8.7±1.7%, and the average discrepancy between investigators was <10%. To quantify aortic lipid accumulation we performed en face analysis. The entire aorta was split longitudinally, pinned flat in a black-waxed dish, and stained with neutral lipid-sensitive stain Oil Red to visualize lesions.
Vessel Morphometry
The aorta length was quantified from the top of the left ventricle until the iliac bifurcation. Aortic valve, thoracic aorta, and brachiocephalic artery (BCA) circumference were quantified at the external elastic lamina using H&E-stained cross sections. 
Immunohistochemistry
Information about antibodies is included in the Major Resources Table in Collagen level in the vascular wall was quantified using Trichromestained aortic rings. Each image was converted into the multichannel mode, and green signal (average pixel value) was assessed from regions of interest manually placed within the image. We kept the same regions-of-interest size to quantify collagen in images obtained for IGF1R-deficient and control mice.
Analysis of Lesions in the BCA
BCA was dissected from SM22α-CreKI/IGF1R-flox (n=10) and FIR (n=8) mice fed with WD for 12 weeks. One hundred five micrometer sections per artery segment were cut, and 10 equally spaced sections were immunostained for calponin, fibrinogen, collagen (Trichrome), and H&E. In addition, serial sections were stained by Carstairs method to detect fibrin (orange-red), SMC (dark red), and collagen (bright blue). Data obtained by IHC were consistent with results generated by Carstairs (data not shown).
Laser Capture Microdissection
The distal end of the small intestine (terminal ileum) was dissected, embedded in optimal cutting temperature compound, and intestinal SMCs were isolated by laser capture microdissection (LCM). Cross section was immunostained for calponin to identify SMC and used as a reference for LCM ( Figure III in the online-only Data Supplement). Eight to 10 serial sections were stained with Histogene staining solution (Thermo Fisher) as per kit's instructions. LCM was performed with the Applied Biosystems ArcturusXT LCM System. LCM dissected tissue was used for RNA isolation with PicoPure Frozen RNA Isolation Kit followed by cDNA synthesis with RiboAmp HS Plus cDNA kit (Thermo Fisher) according to the manufacturer's instructions.
Cytokine Assay
Serum cytokine levels were quantified by Inflammatory Cytokines Multi-Analyte ELISArray (Qiagen) according to manufacturer's instructions. IGF-1 levels were quantified with IGF-1 ELISA (R&D Systems), IGFBP-1 levels with IGFBP-1 DuoSet ELISA (R&D Systems), IGFBP-2 levels with IGFBP-2 ELISA (Thermo Scientific), IGFBP-3 levels with IGFBP-3 Quantikine ELISA (R&D Systems), IGFBP-5 levels with IGFBP-5 ELISA (Sigma-Aldrich), and IGF-1 ALS (acid-labile subunit) levels with ALS ELISA (Biomatek).
Cell Proliferation, Migration, and Cell Apoptosis
Cell apoptosis was quantified with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-Fluorescein Kit (Roche) as per manufacturer's instructions. Total cell apoptosis was defined as TUNEL+ cell number per 1000 plaque cells and, α-SMA-positive cell apoptosis was measured as the number of TUNEL+/α-SMA+ cells per 1000 α-SMA+ cells. Sections treated with DNAse I and sections stained with dUTP-omitted TUNEL mixture served as positive and negative controls for TUNEL assay, respectively. To assess cell proliferation, in vivo labeling of DNA with 5-ethynyl-2′-deoxyuridine (EdU) was performed according to Salic et al. 21 EdU (5 mg/kg per day) was administered intraperitoneally for 4 days before sacrifice, and labeled DNA was detected by AlexaFluor488-azide (Click-It Imaging Kit; Invitrogen). A section of small intestine was the positive control for the EdU assay.
Cell growth curves were built by counting cell number with CyQuant Cell Proliferation Kit (Life Technologies). Cell proliferation was measured with BrdU (5-bromo-2'-deoxyuridine) Cell Proliferation ELISA (Roche). Cell migration was quantified using a wound-healing (scratch) assay as described. 22 Chemoattractant-stimulated cell migration was measured with FluoroBlock plate inserts (BD Biosciences). Cells were seeded on inserts and migrated toward 20% fetal bovine serum for 6 hours followed by labeling with calcein-AM (Molecular Probes). Migrated cell number was quantified on the bottom part of the insert with a Bio-Tek Synergy microplate reader.
Data Analysis
Authors declare that the design, execution, and reporting of the current study adhere to the guidelines for experimental atherosclerosis studies described in the scientific statement from the American Heart Association. 23 Authors considered sex as biological variable in accordance with the statement from the ATVB Council. 24 All numeric data are expressed as mean±SEM. Statistical analyses were performed with GraphPad Prism 6.07. Unless otherwise specified, 2-tailed unpaired Student t tests were performed to determine statistical significance. For data that were not normally distributed, Mann-Whitney U test was performed. ANOVA was used to compare multiple groups followed by post hoc analysis with Dunnett multiple comparison test. We used Grubbs test to check data sets for potential outliers. Differences were considered significant at P <0.05.
Results

SM22α Promoter-Driven Cre Recombinase Decreased IGF1R Expression in SMC and in Fibroblasts
To assess the effects of SMC IGF-1 signaling on the atherosclerotic plaque, we generated Apoe −/− mice with SM22α-CreKImediated IGF1R deficiency (SM22α-CreKI/IGF1R-flox mice, IGF1R/FIR mice). To generate SM22α-CreKI/IGF1R-flox mice, we used SM22α-CreKI +/+ mice, 16 which are widely used for generation of models with SMC-specific knockout. 25, 26 Mice with a LoxP-flanked IGF1R gene (FIR mice) were used as control.
To characterize the phenotype of SM22α-CreKI/IGF1R-flox mice, Cre recombinase and IGF1R expression were quantified in skeletal muscles, spleen, heart, brain, adventitia-free aortas, adventitia, and urinary bladder ( Figure 1 ). Cre recombinase was not found in any tissue dissected from FIR mice. Cre recombinase was detected in SMC-rich tissues (aortas and urinary bladder) and in the heart in SM22α-CreKI/IGF1R-flox mice. Cre expression in the heart of SM22α-CreKI/ IGF1R-flox mice is consistent with the report from Zhang et al 16 showing high Cre expression in aorta and low Cre levels in the heart of SM22α-CreKI +/+ mice. As expected SM22α-CreKI/IGF1R-flox mice have reduced IGF1R expression in the aorta and in the urinary bladder (85±4% and 47±4% decrease, respectively) and also in the heart (51±3% decrease compared with FIR controls) without changes in IGF1R levels in brain, skeletal muscles, and spleen. IGF1R expression was also reduced (78±7% decrease compared with FIR) in nonvascular (intestinal) SMC: cells were identified by immunostaining with calponin (SMC marker) and isolated by LCM 14 ( Figure III in the online-only Data Supplement).
To our surprise, we found detectable Cre expression and reduced IGF1R levels in fibroblast-rich adventitia (43±8% decrease compared with FIR; Figure 1 ) suggesting leakage of Cre in non-SMC tissue. We isolated aortic SMC and also embryonic, skin, and lung fibroblasts from SM22α-CreKI/ IGF1R-flox and control mice. More than 90% aortic cells isolated from SM22α-CreKI/IGF1R-flox or FIR mice were double positive for calponin and α-SMA, SMC markers ( Figure I in the online-only Data Supplement). IGF1R levels were virtually undetectable in SMCs isolated from SM22α-CreKI/IGF1R-flox mice ( Figure 1C ). IGF-1 induced Ser473 Akt and also p38 MAPK and ERK1/2 (extracellular signal regulated kinases 1 and 2) phosphorylation in control cells; however, no Akt and weak p38 MAPK and ERK1/2 activation was found in SM22α-CreKI/IGF1R-flox aortic SMC suggesting inhibition of IGF1R downstream signaling in these cells. IGF1R expression was downregulated by ≈85% in fibroblasts ( Figure 1D and 1E) . Thus, SM22α promoter-driven Cre recombinase induced IGF1R deficiency in SMC and in fibroblasts in SM22α-CreKI/IGF1R-flox mice.
Serum IGF-1 levels were reduced by 24% to 28% in SM22α-CreKI/IGF1R-flox mice compared with control ( Figure IVA in the online-only Data Supplement), and this effect was observed in both males and females (data not shown). IGF-1 is mainly secreted by the liver as a result of stimulation by GH (growth hormone). 12 Besides GH, a group of IGFBPs, and an ALS serve to regulate circulating IGF-1 concentration and action. 12 We measured expression levels of IGF-1, GH, ALS, and IGFBPs in SM22α-CreKI/IGF1R-flox and FIR mice after 12 weeks of feeding with a high-fat WD. IGF-1 gene expression in liver and aortas in SM22α-CreKI/IGF1R-flox mice was not different from controls (data not shown). 
IGF1R Deficiency Induced Growth Retardation, Decrease of Vascular Collagen, and Downregulation of LARP6-a Collagen mRNA-Binding Protein
SM22α-CreKI/IGF1R-flox mice had a basal reduction in body weight compared with FIR mice: 25.8±1.9% decrease at 6 weeks age when fed with normal chow (P<0.05). We observed a similar reduction in body weight for males (SM22α-CreKI/ IGF1R-flox: 14.46±0.68 g; FIR: 19.81±0.35 g; 27.0±2.2% decrease; P<0.05) and for females (SM22α-CreKI/IGF1R-flox: 12.60±0.47 g; FIR: 16.65±0.35 g; 24.3±1.6% decrease; P<0.05). IGF1R-deficient mice had shorter aortas with decreased lumen area, cross-sectional vessel circumference, and reduced area of tunica media compared with control mice. The BCA had also decreased circumference and reduced medial area (Table I in . Skeletal muscles, brain, spleen, adventitia, urinary bladder, heart, and adventitia-free aortas were dissected from FIR and SM22α-CreKI/IGF1R (insulin-like growth factor 1 receptor)-flox (IGF1R/FIR) mice (n=4 per group) and used for immunoblotting (A and B). Aortic SMCs were isolated from mice, and cells were exposed to 100 ng/mL IGF-1 (insulin-like growth factor 1; n=6 per group). Expression of IGF1R and IGF1R downstream molecules was quantified by immunoblotting (C). IGF1R and Cre expression in FBs isolated from FIR and IGF1R/FIR mice (n=4 per group; D and E). MW indicates molecular weight. *P<0.05.
140.1±15.3 g/kg per day; FIR: 152.6±5.23 g/kg per day; P=NS). Feeding mice with a WD for 12 weeks increased body weight in both groups of mice, but SM22α-CreKI/IGF1R-flox mice still had a significant 15.8±1.2% decrease in body weight compared with controls.
To obtain further insights into vascular effects of SM22α-Cre-mediated IGF1R deficiency, we identified SMC and fibroblast in the vascular wall by immunostaining of cross sections of ascending aorta with α-SMA antibody or with TR7 antibody (fibroblast marker 27 ), respectively. The adventitial layer was TR7 immunopositive but α-SMA negative and vice versa, the medial layer was positive for α-SMA and negative for TR7 ( Figure VI in the online-only Data Supplement) indicating that these antibodies are suitable to distinguish SMC and fibroblasts in the vascular wall. SM22α-CreKI/IGF1R-flox mice had a thinner aortic wall (39.1±7.5% decrease compared with FIR mice; P<0.05) because of reduced thickness of both medial and adventitial layers (37.0±3.8% and 43.2±8.6% decrease compared with FIR mice, respectively; both are P<0.05). Although IGF1R deficiency reduced medial area, it did not change either the number of layers in the media (data not shown) or SMC number (SM22α-CreKI/IGF1R-flox: 244.8±13.5 cells; FIR: 252.6±9.2 cells; P=NS) suggesting that SMC size might be smaller in SM22α-CreKI/IGF1R-flox mice. SM22α-CreKI/IGF1R-flox mice had reduced collagen in both media and in vascular adventitia (Figure 2A and 2B) . We have shown that IGF-1 increased collagen in human SMC and in mouse fibroblasts via upregulation of collagen mRNAbinding LARP6 (La ribonucleoprotein domain family, member 6).
28 LARP6 expression was significantly decreased in aortas and in adventitia in SM22α-CreKI/IGF1R-flox mice (>80% decrease compared with FIR mice; Figure 2C and 2E). LARP6 levels were also downregulated by 65% to 75% in embryonic, skin, and lung fibroblasts isolated from SM22α-CreKI/IGF1R-flox mice ( Figure 2D and 2F) . Neither IGF1R deficiency nor mouse feeding with a WD changed systolic blood pressure ( Figure IVD in the online-only Data Supplement).
IGF1R Deficiency Increased Atherosclerotic Burden, Upregulated Plaque Macrophages, and Decreased SMC and Collagen
We tested the effect of IGF1R deficiency on atherosclerosis after 4 weeks and after 12 weeks of mice feeding with a WD. SM22α-CreKI/IGF1R-flox mice had a 3.2-fold increase in lipid accumulation in the aorta (en face analysis, 12 weeks of feeding with WD) and increased atherosclerotic plaque cross-sectional area after 4 and after 12 weeks of WD compared with control ( Figure 3) indicating that IGF1R deficiency promoted atherosclerosis development. We found no sex effect on atherosclerotic burden in SM22α-CreKI/IGF1R-flox or in FIR mice. Atherosclerotic plaques in SM22α-CreKI/IGF1R-flox mice fed for 12 weeks with WD were markedly less cellular than plaques in FIR mice (insert in Figure 3C ); they contained large cholesterol crystals and had increased necrotic cores compared with control. SMC levels were decreased in atherosclerotic plaques in SM22α-CreKI/IGF1R-flox mice fed with WD for either 4 weeks (IHC for α-SMA: 3.1-fold decrease) or 12 weeks (IHC for α-SMA, 2.9-fold decrease; calponin, 2.8-fold decrease; SM-MHC [smooth muscle-myosin heavy chain], 2.7-fold decrease compared with control; Figure 4 ; Figure A and B) and downregulated LARP6 (La ribonucleoprotein domain family, member 6; C-F). A, Cross sections of descending aorta were stained for αSMA (α-smooth muscle cell actin; smooth muscle cell marker), TR7 (FBs marker), and DAPI (4',6-diamidine-2'-phenylindole dihydrochloride) or stained for collagen (trichrome; n=6 per group). LARP6 expression was quantified in adventitia-free aortas, adventitia (C and E), and in embryonic, skin, and lung fibroblasts isolated from mouse tissues (D and F; n=4 per group). Yellow line, tunica media (TM); white line, tunica adventitia (TA). Scale bar=10 um. L indicates lumen. *P<0.05, **P<0.01.
macrophages. To further study molecular mechanism, we quantified expression of 86 chemokines and chemokine receptors in aortic SMCs isolated from SM22α-CreKI/IGF1R-flox and FIR mice using real-time polymerase chain reaction array (Qiagen). We found the strong trend toward upregulation of Ackr4 (atypical chemokine receptor 4), Cxcr3 (C-X-C chemokine receptor type 3), Cxcl12 (C-X-C motif chemokine 12; SDF-1α [stromal cell-derived factor 1α]), and Xcl1 (X-C motif chemokine ligand 1) in IGF1R-deficient SMCs compared with FIR cells (Table  III in the online-only Data Supplement). We confirmed that Ackr4 and Cxcl12 were significantly upregulated in IGF1R-deficient SMCs (10.8-fold and 6.0-fold overexpression, respectively) using real-time polymerase chain reaction (Table IV in the online-only Data Supplement). Cxcl12 (SDF-1α) was involved in regulation of recruitment of inflammatory cells 29 and activation of macrophage phagocytosis. 30 We found that Cxcl12 (SDF-1α) expression was upregulated in αSMA-positive plaque cells in SM22α-CreKI/IGF1R-flox compared with FIR mice fed with WD for 4 weeks (2.1-fold increase; P<0.01; Figure IX in the online-only Data Supplement).
IGF1R Deficiency Stimulated Cell Apoptosis, Reduced Cell Proliferation, and Promoted Inflammatory Responses
α-SMA is expressed by SMC and myofibroblasts in mouse atherosclerotic plaque. 31 Cell apoptosis and cell proliferation of α-SMA-positive cells were quantified by staining with TUNEL assay or with EdU, respectively. SM22α-CreKI/IGF1R-flox mice fed with WD either for 4 or 12 weeks had increased rates of apoptosis and reduced proliferation of α-SMA-positive cells in the atherosclerotic plaque compared with control ( Figure 4B and 4D). Apoptosis and proliferation of α-SMA-negative cells were not changed in mice after 12 weeks of feeding with WD (data not shown). Serum levels of cytokines were quantified in mice fed with WD for 12 weeks using multi-analyte ELISA array. Expression of major proinflammatory cytokines IL (interleukin)-1β, IL-6, and IL-12 was upregulated in SM22α-CreKI/IGF1R-flox mice, and levels of IL-4 and IL-10 (these cytokines can act as proinflammatory and also as anti-inflammatory molecules 32 ) were also increased (Table II in the onlineonly Data Supplement). IGF1R deficiency had no effect on circulating 8-isoprostane levels-a marker of systemic oxidative stress 33 -and did not change serum glucose and total cholesterol levels (Figure X in the online-only Data Supplement).
IGF1R Deficiency Reduced Plaque Fibrous Cap and Increased Necrotic Cores
The reduction in plaque SMC and collagen levels and increase in necrotic cores in IGF1R-deficient mice are consistent with an unstable plaque phenotype. 34 We and others have observed signs of former plaque rupture (such as intraplaque hemorrhage and elastin breaks) in the BCA. 14, 35, 36 BCAs were dissected from SM22α-CreKI/IGF1R-flox and FIR mice, and equally spaced cross sections were stained for calponin to identify SMC-positive plaque fibrous cap ( Figure 5 ). SM22α-CreKI/IGF1R-flox mice had reduced plaque fibrous cap area (53±14% decrease) and increased necrotic cores compared with control mice. Fibrous cap in IGF1R-deficient mice was markedly thinner and contained multiple disruptions ( Figure 5A and 5C). BCA plaques in IGF1R-deficient mice contained reduced collagen levels compared with controls (SM22α-CreKI/IGF1R-flox, 13.1±6.4%; FIR, 48.5±9.3%; P<0.001). We detected minor fibrin deposition (2%-3% of lesion area) in BCA plaques, and IGF1R deficiency did not change fibrin levels ( Figure 
Discussion
Here we report that SMC-and fibroblast-targeted IGF1R deficiency reduced vascular size and vascular collagen content and induced growth retardation. IGF1R deficiency increased atherosclerotic plaque burden and circulating inflammatory cytokines, and these effects were associated with reduced proliferation and elevated apoptosis of α-SMA-positive plaque cells. SMC/fibroblast-targeted decline in IGF-1 signaling decreased plaque SMC, increased necrotic core area and markedly depleted collagen. Consistent with these in vivo findings, we found that aortic SMCs isolated from mice with IGF1R deficiency had disrupted IGF1R-dependent downstream signaling, decreased cell proliferation, migration, and increased sensitivity to apoptosis.
IGF-1 is a potent mitogen and prosurvival factor for vascular SMC and fibroblasts, and it also stimulates migration of SMC 38 and fibroblasts. 39 Thus, a reduction in IGF-1 effects might be beneficial in certain pathological conditions, such as restenosis, hypertension, and the early stages of atherosclerotic plaque formation characterized by hypertrophy/hyperplasia of vascular SMC but detrimental in other conditions in which loss of SMC contributes to the disease process, such as destabilization of atherosclerotic plaques. 40 To assess the role of SMC IGF-1 signaling on the atherosclerotic plaque, we generated mice with IGF1R deficiency induced by Cre recombinase under control of the SM22α promoter (SM22α-CreKI/ IGF1R-flox mice). Cre recombinase expression and corresponding reduction in IGF1R levels were detected in aorta and vascular adventitia in SM22α-CreKI/IGF1R-flox mice, indicating strong activity of the SM22α promoter in SMC-and in fibroblast-rich tissues, and this is consistent with reports showing SM22α expression in vascular SMC 41 and also in adventitial fibroblasts. 42 Further, we found that embryonic, lung, and skin fibroblasts isolated from SM22α-CreKI/IGF1R-flox mice expressed Cre, and these cells also had reduced IGF1R levels. SMCs and fibroblasts play important roles in atherosclerosis via proliferation and migration to the subendothelial region where these cells undergo phenotypic switching: fibroblasts acquire additional SMC markers (including α-SMA) and SMC loose classical smooth muscle markers. 31 We have shown that SM22α immunopositivity was detected in plaque cells in WD-fed Apoe −/− mice, and SM22α was colocalized with other markers of SMC 43 indicating that the SM22α promoter is active in plaque SMC. Thus, SM22α-CreKI/IGF1R-flox mice are a valuable tool to investigate the effect of Cre recombinase-driven IGF1R deficiency in both normal vascular wall SMCs and fibroblasts and in SM22α-expressing plaque cells. SM22α Cre knockin mice are widely used for the generation of murine models with vascular SMC-specific knockout. 25, 26 Our finding that SM22α-CreKI/IGF1R-flox mice (which were derived from SM22α-CreKI +/+ mice 16 ) expressed Cre in both SMCs and in fibroblasts indicates the limited feasibility of using SM22α-CreKI +/+ mice for generation of SMC-specific knockouts. Some prior studies exploring SM22α-CreKI +/+ mice might be potentially reevaluated in view of our current results.
The liver is the major source of circulating IGF-1; however, almost every organ also produces IGF-1, thus there are endocrine (liver derived) and autocrine/paracrine forms of IGF-1. 44 There is debate about the relative role of endocrine vs autocrine/paracrine IGF-1 in body development. Mice with conditional liver-specific IGF-1 knockout (with intact Igf1 gene locus in nonhepatic tissues) had 75% reduction in circulating IGF-1 without changes in body weight 45 showing a dominant role of nonhepatic IGF-1 for normal growth and development. However, Stratikopoulos et al 46 have demonstrated that bitransgenic mice lacking Igf1 gene expression in nonhepatic tissues and partially retaining liver IGF-1 had decreased circulating IGF-1 levels, as well as markedly reduced body weight suggesting that liver-derived and locally produced IGF-1 have at least nearly equal importance for organismal growth. We have shown that SMC isolated from SM22α-CreKI/IGF1R-flox mice had markedly reduced Akt, p38 MAPK, and ERK1/2 phosphorylation indicating that autocrine IGF-1 signaling was inhibited in these cells. Our data are consistent with a critical role of local tissue-specific responses to IGF-1 for entire body development. Our current report demonstrates the importance of autocrine/paracrine SMC/fibroblast IGF-1 signaling for organismal growth. Of note, SM22α transcripts are expressed transiently in the embryonic heart (between embryonic day [E] 8.0 and E12.5) in skeletal muscle cells in the somites (E9.5-E12.5) and in vascular SMC beginning E9.5, and thereafter, they continue to be expressed in all SMCs into adulthood. 47, 48 One can speculate that activation of the SM22α promoter during embryogenesis in SM22α-CreKI/IGF1R-flox mice contributed to mechanisms inducing growth retardation. Our data show that IGF1R deficiency reduced overall vascular size, and in particular, medial area, although the number of nuclei/media was unchanged, potentially suggesting a reduction in individual cell size. SM22α-CreKI/IGF1R-flox-derived aortic SMC had reduced proliferation rate and increased sensitivity to apoptosis and these mechanisms could contribute to growth retardation. Furthermore, intriguingly, we found that SM22α promoter-driven deficiency of IGF1R reduced circulating IGF-1 levels. IGF1R deficiency had no effect on IGF-1 production by the liver. We found no changes in expression of IGFBP-3 and ALS (these molecules form the ternary IGF-1/ IGFBP-3/ALS complex-the primary stabilizer of circulating IGF-1 12 ); however, IGFBP-5 levels were decreased in SM22α-CreKI/IGF1R-flox mice. IGFBP-5 is known to form an alternative complex with ALS in the presence of IGF-1, competing with IGFBP-3. 49 IGFBP-5 overexpressing mice have increased circulating IGF-1 levels suggesting the ability of IGFBP-5 to regulate circulating IGF-1 levels, 50 and it is known that IGF-1 can also regulate IGFBP-5 levels. 51 It is thus difficult to know whether the reduction in circulating IGF-1 resulted in a decrease in IGFBP-5 or vice versa. We have shown that IGF-1 exerts antiatherogenic effects in Apoe −/− mice, and IGF-1-induced reduction in atherosclerotic burden was associated with suppression of inflammatory responses, reduced cell apoptosis, decrease in plaque macrophages, increase in SMC, and vascular collagen. 6, 7, 52 In the current study, we found that SM22α-CreKI-mediated loss of IGF-1 signaling increased atherosclerosis and cell apoptosis, reduced plaque SMC and collagen, increased plaque macrophages, and potentiated inflammation. Because these effects are attributed to SMC and fibroblasts, our results demonstrate a key role of these cells in mediating IGF-1-induced atheroprotection. It is important to outline that increased sensitivity to apoptosis of SM22α-CreKI/IGF1R-flox-derived aortic SMC was associated with inhibition of IGF-1-induced Akt signaling. We have demonstrated previously that the antiapoptotic function of the IGF1R was mediated by PI3-kinase/Akt signaling in human aortic SMC. 53 These in vitro data taken together with results of the current study are consistent with an important role of IGF-1/IGF1R/Akt signaling for SMC resistance to apoptosis.
SMC-derived cytokines/chemokines have been reported to modulate macrophage recruitment and phenotype. 29, 54 We have found that Cxcl12 (SDF-1α) chemokine was upregulated in aortic SMCs isolated from SM22α-CreKI/IGF1R-flox mice and in αSMA+ plaque cells in these mice. Different cell types, including vascular SMCs and monocytes, express Cxcl12 and its main receptor Cxcr4.
55 Cxcl12/Cxcr4 axis has been . IGF1R (insulin-like growth factor 1 receptor) deficiency reduced smooth muscle cell (SMC) proliferation, decreased cell migration, and increased apoptotic rates. SMCs were isolated from mouse aortas. Cell growth curves were obtained by counting cell number (A), and cell proliferation was assessed by DNA labeling with BrdU (5-bromo-2'-deoxyuridine) ELISA (B; n=6 per group). Cell migration was measured using a wound-healing (scratch) assay as the percentage of scratch area, which was left unoccupied (n=6 per group). Chemoattractant-stimulated cell migration was quantified toward 20% fetal bovine serum using FluoroBlock plate inserts (C). To quantify apoptosis, aortic SMCs were incubated with/without H 2 O 2 and stained with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (n=4 per group; D). *P<0.05, **P<0.01, ***P<0.005.
implicated in recruitment of inflammatory cells 29 and formation of macrophage-derived foam cells. 56 Plaque macrophages were identified in this study by immunohistochemistry for Mac-3 (macrophage marker 3; CD107b)-general macrophage marker. 57 Mac-3 is also expressed by some dendritic cells. 58 Dendritic cells are known to express Cxcr4 and respond to Cxcl12. 59, 60 Dendritic cells play the important role in all stages of atherosclerosis, including lipid uptake, antigen presentation, efferocytosis, and inflammation resolution. 61 We speculate that IGF1R deficiency stimulated Cxcl12/Cxcr4 signaling pathway, and this mechanism promoted recruitment of inflammatory cells and increased the number of Mac-3-positive plaque cells in SM22α-CreKI/IGF1R-flox mice. We have found that IGF1R deficiency induced a relatively large increase in the number of apoptotic aSMA+ plaque cells (from 0.4% to 1.2% at 4 weeks of WD). It has been shown that an increase in SMC apoptosis (from 1.2% to 2.3% at 10 weeks of WD) was sufficient to increase plaque size in Apoe-null mice. 62 Therefore, our data suggest that elevated SMC apoptosis and an increase in plaque macrophages are responsible for increased atherosclerotic plaque burden seen in SM22α-CreKI/IGF1R-flox mice.
In advanced atherosclerotic plaques, a balance between cell death and survival of cells within the fibrous cap, primarily composed of vascular SMC and extracellular matrix, seems to correlate with plaque instability or stability. 62 We have shown that SMC-specific IGF-1 overexpression did not change atherosclerotic burden; however, plaques in IGF-1 overexpressing mice had increased SMC levels, collagen content, and reduced necrotic cores suggesting that SMC-derived IGF-1 promoted plaque stability. 43 SMC-derived IGF-1 may act in an autocrine manner (on SMC) and in a paracrine manner on neighboring fibroblasts, monocytes/macrophages, endothelial cells, and others. Our current study demonstrates that SMC and fibroblast IGF-1 signaling plays a critical role in antiatherosclerotic and plaque stabilizing effect of IGF-1.
IGF-1 upregulated collagen mRNA-binding protein LARP6 in cultured aortic SMCs, mouse fibroblasts, and also in vivo in Apoe −/− mice, and LARP6 upregulation mediated IGF-1-induced increase in collagen. 28 In the current study, we found that IGF1R deficiency reduced α-SMA-positive cells, increased necrotic cores, and depleted collagen in atherosclerotic plaque suggesting decreased plaque stability. We found that SM22α-CreKI/IGF1R-flox mice had a reduced fibrous cap area, increased necrotic cores, and thinner fibrous caps consistent with the unstable plaque phenotype. It is important to note that these effects correlated with marked downregulation of LARP6 in aortas, vascular adventitia, and also in embryonic, skin, and lung fibroblasts. Taken together, these findings established the potential link between SMC/ fibroblast LARP6 and plaque stability and justify further investigation into the role of LARP6 in promoting plaque stabilization.
In summary, we assessed effects of SM22α-CreKImediated IGF1R deficiency on vascular wall morphology and atherosclerotic plaque development. A decline in SMC and fibroblast IGF-1 signaling reduced overall vascular size, decreased SMC proliferation, increased apoptotic rates, and furthermore resulted in mouse growth retardation.
The high-fat diet-fed SM22α-CreKI/IGF1R-flox mice had increased inflammatory responses and atherosclerotic burden. Atherosclerotic plaques in SM22α-CreKI/IGF1R-flox mice had larger necrotic cores, increased macrophages, decreased SMC levels, and markedly depleted collagen indicating that IGF1R downregulation potentially compromised plaque stability. Our data demonstrate the important role of IGF-1 signaling in SMC and in fibroblasts for normal vascular wall development and for prevention of atherogenesis.
